Here are the 424B prospectus supplements from vTv Therapeutics Inc. (VTVT) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow VTVT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VTVT filings page.
vTv Therapeutics Inc. is offering up to $47,500,000 of Class A common stock in an at-the-market offering through TD Cowen pursuant to a sales agreement dated previously. Sales may occur from time to time, with TD Cowen acting as agent or principal and receiving a 3.0% commission.
The prospectus supplement assumes for illustration the sale of 1,559,422 shares at the last reported sale price of $30.46 per share and states there were 3,938,654 shares outstanding as of March 31, 2026. Net proceeds are intended for general corporate purposes, including funding development and trials for cadisegliatin.